Reshape Lifesciences Inc   (RSLS)
Other Ticker:  
Price: $0.1705 $0.00 2.157%
Day's High: $0.1732 Week Perf: 3.96 %
Day's Low: $ 0.17 30 Day Perf: -0.87 %
Volume (M): 181 52 Wk High: $ 2.80
Volume (M$): $ 31 52 Wk Avg: $0.84
Open: $0.17 52 Wk Low: $0.14

 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 6
 Employees -
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Reshape Lifesciences Inc
Reshape Lifesciences Inc is a medical technology company that focuses on developing and commercializing innovative medical devices to treat obesity and metabolic diseases. Their main product is the ReShape' Integrated Dual Balloon System, which is designed to aid in weight loss by occupying space in the stomach and making patients feel full. The company aims to provide non-surgical solutions for patients struggling with obesity, offering an alternative to traditional weight loss methods. In addition to their primary product, Reshape Lifesciences Inc also offers related services such as patient support programs and physician training to ensure successful patient outcomes.

   Company Address: 18 Technology Dr. Suite 110 Irvine 92618 CA
   Company Phone Number: 429-6680   Stock Exchange / Ticker: NASDAQ RSLS


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Reshape Lifesciences Inc

Revenue Plummets at Reshape Lifesciences Inc Amid Fiscal Quarter Ending December 31, 2023

Reshape Lifesciences Inc, a medical equipment and supplies company, recently reported its financial results for the fourth quarter of 2023. The company showed improvement in its earnings per share, with a decrease in the loss per share from $-0.86 a year ago to $-0.11 per share. Additionally, the EPS improved from $-1.02 per share in the prior quarter.
In terms of revenue, Reshape Lifesciences Inc experienced a decline of -38.521% to $1.91 million compared to $3.11 million in the same quarter a year ago. Sequentially, the revenue also deteriorated by -11.276% from $2.16 million. Despite this decline, the company reported a net deficit of $-1.698 million, a significant improvement from the deficit of $-16.612 million in the comparable quarter a year ago.

Management Announcement

Reshape Lifesciences: A Promising Rebirth towards Profitability in the Healthcare Market

Published Mon, Mar 4 2024 1:31 PM UTC

Reshape Lifesciences: A Promising Turnaround in the Making
In a recent announcement, Reshape Lifesciences provided an update on its 2024 cost reduction plan and reorganization strategy, signaling a significant shift towards the commercialization of its Lap-Band 2.0 FLEX. With the aim of prioritizing profitability, the company expects operating expenses to decrease b...

Merger and Acquisition

ReShape Lifesciences Collaborates with Maxim Group LLC to Explore Lucrative M&A Opportunities

Published Wed, Dec 20 2023 1:31 PM UTC

In a groundbreaking move, ReShape Lifesciences Inc. (Nasdaq: RSLS), the leading physician-led weight loss and metabolic health-solutions company, has engaged Maxim Group LLC as its exclusive financial advisor. This strategic partnership aims to identify potential merger and acquisition options that will further enhance ReShape Lifesciences' position in the market. ...

Reshape Lifesciences Inc

Revolutionary Medical Equipment & Supplies Firm: Dwindling Revenues in Q3 2023 Raises Eyebrows

Reshape Lifesciences Inc, a medical equipment and supplies company, recently reported its financial results for the most recent fiscal period. The company experienced a rise in losses due to weak orders, causing a net deficit per share to increase from $-0.52 to $-1.02. Additionally, revenue dropped by -22.981% to $2.16 million compared to $2.80 million in the previous year.
The decline in revenue for Reshape Lifesciences Inc is in stark contrast to the on average revenue gain recorded by the Medical Equipment & Supplies sector. While the sector as a whole saw an increase in revenue, Reshape Lifesciences Inc suffered a slump in their top-line. This disparity may raise concerns about the company's ability to compete effectively within the industry.

Reshape Lifesciences Inc

Reshape Lifesciences Inc Reports Gloomy -24.136% Drop in Revenue, Indicating Challenging Market Environment

Financial news report:
Weak demand caused an increase in losses for Reshape Lifesciences Inc in the financial time-frame ending June 30, 2023. The company's shortfall per share rose to $-1.08 from $-0.50, while revenue fell by -24.136% to $2.19 million from $2.89 million a year before. This decline in revenue can be attributed to the challenging market environment faced by Reshape Lifesciences Inc.
In contrast to RSLS's scenario, the overall Medical Equipment & Supplies industry posted a revenue growth of 4.21% relative to the corresponding period a year ago in the second quarter of 2023. This indicates that the industry as a whole has been more successful in generating revenue compared to Reshape Lifesciences Inc.


Reshape Lifesciences Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Reshape Lifesciences Inc does not provide revenue guidance.

Earnings Outlook
Reshape Lifesciences Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com